INTRODUCTION
============

Primary gastric melanoma (PGM) is extremely rare, with few reported cases. PGM tends to metastasise early and has a poor outcome. We present the case of a patient whom an extensive work-up concluded PGM, with a rare *BRAF* V600R mutation. While *BRAF* mutations are common in cutaneous melanoma^\[[@b1-749-1-4653-2-10-20171229]\]^, they are rare in mucosal melanomas, and have not previously been described in a PGM.

CASE DESCRIPTION
================

A 76-year-old male patient presented with a one-month history of fatigue, exertional dyspnoea and weight loss. He had iron deficiency anaemia. At gastroscopy, there was a large ulcerated lesion in the proximal stomach ([Fig. 1](#f1-749-1-4653-2-10-20171229){ref-type="fig"}). Histological examination revealed extensive lamina propria infiltration by a population of large epithelioid malignant cells. Immunohistochemistry was positive for S100 Protein, HMB-45, and Melan-A, consistent with malignant melanoma. Further genetic analysis revealed a V600R mutation at exon 15 of the BRAF gene.

Work-up, including a full skin examination and ophthalmology review, did not identify another primary source, and no metastatic disease was identified on radiological imaging. The consensus diagnosis of the treating physicians and surgeons was that findings were consistent with PGM. Subsequently, he underwent an open sleeve gastrectomy, and histology confirmed a melanomatous process, with two positive local lymph nodes.

Following post-operative recovery and prior to commencement of systemic treatment, a repeat CT scan of the thorax, abdomen and pelvis showed interval progression of the disease in the two-month interval, with new liver metastases and an enlarging left upper quadrant deposit. The patient commenced immunotherapy, but unfortunately died of disease progression within a few months.

DISCUSSION
==========

Melanoma is an aggressive neoplasm that usually occurs in cutaneous sites, but can also arise from other less common sites such as uveal tracts and mucosa. Mucosal melanoma accounts for only 1.3% of all these cases, tends to present with advanced disease, and generally has a very poor prognosis^\[[@b2-749-1-4653-2-10-20171229]\]^. PGM, a subtype of mucosal melanoma, is an even rarer occurrence, with only sporadic case reports in the literature^\[[@b3-749-1-4653-2-10-20171229]\]^.

PGM presents similarly to other upper gastrointestinal lesions, with weight loss, abdominal pain, and melaena. If histology is diagnostic of melanoma, it is important to exclude metastasis from a primary cutaneous or ocular lesion, with full skin examination by a dermatologist and an ophthalmological assessment to outrule another primary source, as this influences both the prognosis and further management, including whether surgical resection is advisable. Detailed radiological imaging is performed to delineate the burden of metastases, if indicated by histology.

Genetic testing of melanoma is mandatory as it informs the treatment paradigm, with targeted therapies available for patients exhibiting specific mutations. Ninety per cent of all mutations are acquired, due to the effects of cumulative environmental factors, such as exposure to ultraviolet light. Mucosal melanomas have been found to exhibit different genetic mutations to their cutaneous counterparts, suggesting differing tumour biology^\[[@b2-749-1-4653-2-10-20171229]\]^. Approximately 50% of cutaneous melanomas have a *BRAF* mutation^\[[@b4-749-1-4653-2-10-20171229]\]^, whereas *BRAF* mutations are rare in mucosal melanomas^\[[@b1-749-1-4653-2-10-20171229]\]^. The *BRAF* oncogenic effect is exerted through increased activation of the MAP kinase pathway, leading to uncontrolled cell proliferation^\[[@b5-749-1-4653-2-10-20171229]\]^. Several *BRAF* mutations have been described, with V600E accounting for over 80% of mutations^\[[@b4-749-1-4653-2-10-20171229]\]^. The V600R mutation (a substitution of arginine for valine at codon 600 of the *BRAF* gene) was identified in this patient, and accounts for approximately 4% of all melanoma cases^\[[@b6-749-1-4653-2-10-20171229]\]^, and, to our knowledge, has not been previously described in a PGM.

There is no clear consensus on the management of PGM. In this case, the disease progressed rapidly despite management with surgery and immunotherapy, consistent with the scanty literature which suggests a uniformly poor prognosis.
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